---
type: "Topics"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/topics/39995078.md"
description: "$Sarepta医疗(SRPT.US) | 萨雷普塔：H.C. Wainwright 重申卖出评级，维持目标价在$5分析师认为，新的罗氏研究带来了日益增加的有效性风险，其核心美国 ELEVIDYS 特许经营权的上行空间有限，下行风险显著。来源：Hardik Shah"
datetime: "2026-04-17T11:17:30.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39995078.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39995078.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39995078.md)
author: "[Hardik Shah](https://longbridge.com/zh-CN/profiles/27423834.md)"
---

# $Sarepta医疗(SRPT.US) | 萨雷普塔：H.C. Wainwright 重申卖出评级，…


### 相关股票

- [SRPT.US](https://longbridge.com/zh-CN/quote/SRPT.US.md)
- [RHHBY.US](https://longbridge.com/zh-CN/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/zh-CN/quote/RHHVF.US.md)